前壁心肌梗死合并院前心脏骤停患者在接受家庭自动体外除颤器试验中的结局
该研究基于HAT试验队列,纳入6849例前壁心梗患者,其中650例(9.5%)在入组前急性期发生心脏骤停。Cox模型显示,骤停组与无骤停组的调整后全因死亡(HR 0.95,95%CI 0.65-1.38)和心源性猝死(HR 1.12,95%CI 0.68-1.83)风险无差异。亚组分析发现,植入ICD后骤停组全因死亡风险显著升高(HR 5.01,95%CI 1.05-23.79),而未植入ICD者两组无差异(HR 0.89,95%CI 0.60-1.31),交互作用P=0.035。提示前壁心梗后心脏骤停并非独立预后恶化因素,但ICD植入与更高死亡风险相关,需谨慎评估。
要点
- 前壁心梗合并急性期心脏骤停患者,调整后全因死亡风险与无骤停者无显著差异(HR 0.95,95%CI 0.65-1.38)。
- 心源性猝死风险同样无显著差异(HR 1.12,95%CI 0.68-1.83)。
- 植入ICD后,骤停组全因死亡风险显著高于无骤停组(HR 5.01,95%CI 1.05-23.79)。
- 未植入ICD者,两组全因死亡风险无差异(HR 0.89,95%CI 0.60-1.31),交互作用P=0.035。
- 约48%的骤停事件发生在入组前1年内,71%为院内骤停。
适用人群与场景
- HAT试验纳入的前壁心肌梗死患者,且未接受或为ICD候选者。
- 本队列为入组前急性期发生心脏骤停的患者。
- 排除标准原文未提及。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:HAT试验队列分析,样本量6849例,骤停组650例(9.5%)。
- 人群:前壁心梗患者,未接受或为ICD候选者,入组前急性期发生心脏骤停。
- 干预与对照:比较MI-SCA与MI-no SCA患者,主要终点为全因死亡和心源性猝死。
- 主要结果:调整后全因死亡HR 0.95(95%CI 0.65-1.38),心源性猝死HR 1.12(95%CI 0.68-1.83),均无显著差异。
- 亚组:植入ICD后,MI-SCA组全因死亡HR 5.01(95%CI 1.05-23.79);未植入ICD组HR 0.89(95%CI 0.60-1.31),交互作用P=0.035。
- 其他:约48%的骤停事件在入组前≤1年,71%为院内骤停;MI-SCA组更年轻、白人更多、既往PCI率更高。
证据类型、等级与局限
- 证据类型:基于随机对照试验HAT的队列分析。
- 局限:原文未明确提及局限;设计为回顾性队列分析,可能存在混杂。
对床旁实践的改变
- 前壁心梗合并急性期心脏骤停患者,调整后死亡风险与无骤停者相似,不应仅因骤停史而判定预后更差。
- 植入ICD后骤停组死亡风险更高,提示对该类患者植入ICD需谨慎评估获益与风险。
- 未植入ICD者两组死亡风险无差异,支持根据指南评估ICD适应证。
指南或共识出处
- Home Automated External Defibrillator Trial (HAT)
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with sudden cardiac arrest occurring in the acute phase of myocardial infarction (MI-SCA) are believed to be at similar risk of death after revascularization compared with MI patients without SCA (MI-no SCA). Among patients with anterior MI, we examined whether those with MI-SCA were at greater risk of all-cause mortality or sudden cardiac death (SCD) than MI-no SCA patients.
METHODS: The Home Automated External Defibrillator Trial enrolled patients with anterior MI who had not received or were candidates for an implantable cardioverter defibrillator (ICD). Our cohort included patients with a reported SCA event, in the acute phase of an MI, prior to HAT trial enrollment. Cox proportional hazards models examined the adjusted association between MI-SCA versus MI-no SCA patients and all-cause mortality and sudden cardiac death (SCD). We also determined whether the relationship between prior SCA and outcomes changed with subsequent events (syncope, revascularization, and recurrent MI) during follow-up.
RESULTS: Of 6849 patients, 650 (9.5%) had MI-SCA before trial enrollment. Approximately 48% of patients had the MI-SCA event ≤1 year prior to enrollment; 71% of SCA events were in-hospital. MI-SCA patients were younger, more frequently white, and had higher rates of prior PCI versus MI-no SCA patients. There were no differences in adjusted all-cause mortality (hazard ratio [HR 0.95; 95% CI 0.65-1.38]) or SCD (HR 1.12; 95% CI 0.68-1.83) for MI-SCA vs. MI-no SCA. After ICD implantation, MI-SCA patients experienced higher all-cause mortality risk (HR 5.01, 95% CI 1.05-23.79) versus MI-no SCA patients; there was no mortality difference between MI-SCA and MI-no SCA patients without ICD implantation (HR 0.89, 95% CI 0.60-1.31), [interaction p = 0.035].
CONCLUSIONS: Patients with MI-SCA had similar adjusted risk of all-cause mortality and SCD compared with MI-no SCA. After ICD implantation, MI-SCA patients had higher mortality compared with MI-no SCA patients.
参考来源
- Starks MA, Jackson LR, Hellkamp A, et al. Outcomes for patients with anterior myocardial infarction and prior cardiac arrest in the home automated external defibrillator trial (HAT). Resuscitation. 2021. PMID: 34500022. doi:10.1016/j.resuscitation.2021.08.047
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。